The US Food and Drug Administration has announced the approval of vandetanib from AstraZeneca Plc for the treatment of patients with late-stage medullary thyroid cancer who are ineligible for surgery. The decision was announced on 6 April. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
